Mediolanum International Funds Ltd Invests $5.95 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mediolanum International Funds Ltd acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 38,556 shares of the biopharmaceutical company’s stock, valued at approximately $5,953,000.

Several other institutional investors have also modified their holdings of the company. Harbor Capital Advisors Inc. lifted its position in shares of Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 51 shares during the last quarter. EP Wealth Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.4% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 71 shares during the last quarter. Commerce Bank lifted its position in shares of Alnylam Pharmaceuticals by 1.7% during the 4th quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 77 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Alnylam Pharmaceuticals by 7.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 89 shares during the last quarter. Finally, Metis Global Partners LLC lifted its position in shares of Alnylam Pharmaceuticals by 2.2% during the 4th quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 1.2 %

Shares of ALNY traded up $3.02 on Wednesday, hitting $257.76. 926,710 shares of the stock traded hands, compared to its average volume of 887,892. The firm has a market capitalization of $32.60 billion, a P/E ratio of -96.18 and a beta of 0.37. The stock’s 50 day moving average is $174.57 and its two-hundred day moving average is $167.75. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $257.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. The business’s quarterly revenue was up 54.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.40) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.92 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ALNY. Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research report on Friday, June 28th. Royal Bank of Canada boosted their price target on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company an “outperform” rating in a research report on Tuesday, June 25th. Cantor Fitzgerald reissued a “neutral” rating and issued a $150.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, July 1st. Finally, Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.32.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,357 shares of company stock valued at $13,436,711. Company insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.